After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week.
Recursion Pharmaceuticals (NASDAQ: RXRX) has been a pioneer in using artificial intelligence (AI) to improve the drug ...
As many veteran investors can attest, biotech stocks are tricky to trade. Their potential upside is enormous, but so is their risk. Too many of these names end up being complete busts. If you pick the ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Recursion reported fourth-quarter revenue of $10.89 million, which missed the consensus estimate of $20.35 million. The company reported a quarterly loss of 42 cents per share, which beat estimates ...
Recursion reports fourth-quarter revenue of $10.89 million, missing the consensus estimate of $20.35 million. The company reports a quarterly loss of 42 cents per share, beating estimates for a loss ...
Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical stage company that mixes healthcare with technology and artificial intelligence (AI). Its drug discovery platform, Recursion OS, is the key to ...
AI is revolutionizing healthcare, with Recursion Pharmaceuticals leveraging AI and vast datasets for drug discovery, making it a compelling investment opportunity. Recursion's integrated drug ...
Recursion Pharmaceuticals (RXRX) closed the latest trading day at $5.41, indicating a -1.64% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss ...
If you are eyeing Recursion Pharmaceuticals and wondering whether now is the time to act, you are not alone. The stock just staged a remarkable run, up 20.8% over the past week and soaring 36.0% ...
For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.